JOURNAL ARTICLE
VALIDATION STUDIES
Add like
Add dislike
Add to saved papers

Gender-related differences in pharmacokinetics, tissue distribution, and excretion of 20(R)-25-methoxyl-dammarane-3β,12β,20-triol and its metabolite in rats and anti-ovarian cancer evaluation.

Our previous study suggests a well-defined pharmacological activity of 20(R)-25-methoxyl-dammarane-3β,12β,20-triol (AD-1) and its metabolite 20(R)-dammarane-3β,12β,20,25-tetrol (AD-2). The current study aims to investigate the gender-related differences in pharmacokinetics, tissue distribution, and excretion of AD-1 and its metabolite in both male and female rats. A sensitive and rapid ultra-performance liquid chromatography tandem mass spectrometric (UPLC-MS/MS) method was developed for the simultaneous determination of AD-1 and AD-2 levels in plasma, various tissues, bile, urine, and feces. The results showed that AD-1 and its metabolite were rapidly distributed and eliminated from rat plasma; linear dynamics (r ≥ 0.8042) was observed in the dose range of 10-40 mg/kg. Compared with male rats, AD-1 and AD-2 were eliminated slowly from the plasma of female rats, and significant gender-related differences were observed in the pharmacokinetics as well as tissue distribution, however, long-term accumulation was not observed. Gender also significantly influenced excretion via urine and feces, but this effect was not observed in the bile excretion study. In rats, AD-1 and its metabolite were highly distributed in female genital organs, which implied that AD-1 and AD-2 might have a great potential for the treatment of ovarian cancer. Therefore, this study first investigated the in vitro activity of AD-1 and AD-2 for ovarian cancer. The results indicated that AD-1, AD-2, and Mitomycin C (Mito C) obviously inhibited the growths of ovarian cancer cells (HO-8910 and OVCAR(R)-3). At 40, 80 μM, AD-1, AD-2 reduced growth of two ovarian Cancer cells by 80%, were more effective than Mito C, and AD-1 showed stronger anti-ovarian cancer cell activity than AD-2. The results provide a theoretical basis for the future studies of AD-1 and AD-2 in ovarian cancer.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app